Frontline Ibrutinib Plus Obinutuzumab Improves PFS in Phase III CLL Trial
Frontline treatment with the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) improved progression-free survival compared with chlorambucil plus obinutuzumab in patients with CLL or SLL.
Source: OncLive